Attached files
| file | filename |
|---|---|
| 10-Q - 10-Q - Verona Pharma plc | vrna-20210331.htm |
| EX-32.2 - EX-32.2 - Verona Pharma plc | exhibit322q121.htm |
| EX-31.2 - EX-31.2 - Verona Pharma plc | exhibit312q121.htm |
| EX-31.1 - EX-31.1 - Verona Pharma plc | exhibit311q121.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Verona Pharma plc (the “Company”) for the period ended March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| Date: April 29, 2021 | By: | /s/ David Zaccardelli, Pharm.D. | |||||||||
| David Zaccardelli, Pharm.D. | |||||||||||
Chief Executive Officer (principal executive officer) | |||||||||||